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The discovery of small molecule and biologic drugs offers
treatments applicable to a wide variety of infectious and
chronic human diseases. Antibiotics have, since World War
II, been the weapons of choice in humanity’s on-going battle
with pathogenic bacteria, and more recently the discovery of
antiviral drugs has been an area of active endeavor. Yet the
emergence ofmultiresistant bacteria, aswell as the continuing
prevalence of antigenic drift in viruses, has shown the funda-
mental limitations of postinfection drug therapy. Fortunately,
the scientific exploitation of host immunity provides an even
more powerful approach to forestalling infection and coun-
teracting chronic disease states.The supreme embodiment of
this is the vaccine. Indeed, prophylactic, and to a lesser extent
therapeutic, vaccines continue to be the most cost-effective
and efficient alternative to other medicines for the treatment
and prevention of infectious diseases, cancer, and allergy con-
ditions. Importantly, unlike drug-based medicines, vaccines
are primarily curative not palliative remedies.
Vaccines work by inducing profound changes in the cel-
lular components of adaptive immunity, comprising T- and
B-cells. The first vaccines targeted infections pathogens and
were composed of killed or attenuated pathogens. However,
our emerging understanding of antigen presentation and sub-
sequent recognition has enabled the development of several
new types of vaccine, including those based on single proteins
or on synthetic peptides encompassing many B- and T-cell
epitopes [1]. Peptide-based epitope ensemble vaccines offer
several potential advantages over traditional whole-organism
vaccines. Chiefly, they allow the immune response to focus
solely on relevant epitopes, avoiding those that lead to
nonprotective responses, immune evasion, or unwanted side
effects, such as autoimmunity. Consequently, peptide-based
vaccines in particular offer renewed hope for the treatment
and prevention of chronic infectious diseases such as those
caused by hepatitis C virus and cancer [2, 3]. Likewise,
peptide-based vaccines can also be used as safer ways of
inducing allergen specific tolerance [3].
The design of peptide-based vaccines takes advantage of
an emergent computational paradigm that couples immu-
noinformatic prediction with rigorous experimental valida-
tion, thus facilitating the identification of epitopes within
protein antigens [1]. Amongst extant prediction technologies,
the most fruitful has been data-driven prediction of T-cell
epitopes. T-cell epitope prediction relies primarily on the
anticipation of peptide-binding to MHC molecules [4] and
many methods drawn from bioinformatics and/or chemoin-
formatics are known to produce satisfactory results [5, 6].
However, development of effective peptide-based vac-
cines requires science to overcome a number of significant
difficulties, including identifying optimal delivery routes,
overcoming the low intrinsic immunogenicity of individual
peptides, and the task of combining different types of epitopes
to engage the humoral and cellular arms of the adaptive
immune response properly, as well as compensating for the
poor population coverage of individual T-cell epitopes due to
MHC restriction. On amore technical level, certain antigenic
Hindawi Publishing Corporation
Journal of Immunology Research
Volume 2014, Article ID 256784, 2 pages
http://dx.doi.org/10.1155/2014/256784
2 Journal of Immunology Research
epitopes, specifically B-cell epitopes or antibody determi-
nants, are conformational and need to be mimicked by lin-
ear sequences or placed onto suitable spatial frameworks.
Moreover, methods for predicting B-cell epitopes need to
be improved as they are notoriously unreliable in predicting
both linear [7] and conformational [8, 9] B-cell epitopes.
In this special issue on peptide-based vaccines, we have
gathered together a varied array of cutting-edge reports
and reviews detailing several important and innovative
approaches to the design and discovery of epitope-based vac-
cines. Articles range from reports on new computational
methods for epitope prediction and selection for vaccine
design to clinical trials using peptide-based vaccines.
We hope that readers will find this special issue not
only interesting but also enlightening, exciting, and inspiring.
As more and more pathogen genomes are revealed and
our understanding of fundamental immunological mech-
anisms deepens, it becomes ever clearer that the only
tractable approach to vaccine discovery and design is through
the interplay of in silico with in vitro and in vivo techniques.
Indeed, the combination of computational and experimental
epitope mapping offers many tools and techniques appro-
priate to the identification and optimization of vaccine
candidates. As this special issue demonstrates so well, such
methodology is fast becoming one of the most pivotal tools
currently available to vaccine developers; and it foreshadows
the day when this variety of approaches will fully synergize to
speed up the development of powerfully efficacious vaccines
against both infective and chronic disease states.
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